Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IDVYNSO vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of schizophrenia,Adjunctive treatment of major depressive disorder
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Primarily hepatic via CYP3A4 and CYP2D6
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 85% bound, primarily to albumin and α1-acid glycoprotein.
82–88% bound to plasma proteins (primarily albumin).
Vd = 1.5–2.5 L/kg, indicating extensive tissue distribution.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 75–85% (first-pass effect minimal); intravenous: 100%.
Oral: 65–80% (median 73%)
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59: 2.5 mg/kg IV once daily for 28 days. Cr Cl < 30: not recommended.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg/kg IV once daily for 28 days. Child-Pugh C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Not approved for pediatric use. Safety and efficacy not established.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment required; monitor renal function due to age-related decline. Use lowest effective dose.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
None
None
May cause QT prolongation; monitor ECG. Risk of extrapyramidal symptoms. Caution in patients with hepatic impairment.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Concurrent use with strong CYP3A4 inducers. History of QT prolongation or torsade de pointes.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid tyramine-rich foods: aged cheeses, cured meats (e.g., salami, pepperoni), fermented foods (e.g., sauerkraut, kimchi), soy products, broad bean pods, draft beers, and red wine. Tyramine can cause hypertensive crisis when combined with IDVYNSO.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Contraindicated in pregnancy.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants; discontinue breastfeeding or discontinue drug.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No dose adjustment recommended; use is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance and volume of distribution) may require dosage increase if used for life-threatening conditions, but alternative therapy is preferred.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
IDVYNSO is a reversible inhibitor of monoamine oxidase A (RIMA); avoid concurrent use with sympathomimetics and tyramine-rich foods. Monitor for hypertensive crisis; discontinue 5 days before elective surgery. Use with caution in patients with hepatic impairment.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Do not take with other antidepressants, especially MAOIs, SSRIs, or SNRIs.,Avoid foods high in tyramine such as aged cheeses, cured meats, and fermented products.,Report sudden severe headache, palpitations, or chest pain immediately.,Take with food to minimize nausea; do not crush or chew tablets.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IDVYNSO vs AGRYLIN, answered by our medical review team.
IDVYNSO is a Antineoplastic Agent that works by IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IDVYNSO and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IDVYNSO is: 5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IDVYNSO and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IDVYNSO is classified as Category C. Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: risk of . AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.